Dr. Nadège Pelletier holds a PhD in immunology from Claude Bernard University, ENS-Lyon, France, and a Master of Science in Genetics and Immunology from ENS-Lyon. She is a cellular immunologist by training and has extensive experience in the areas of infectious diseases, autoimmunity, and inflammation. Dr. Pelletier joined Barinthus Biotherapeutics as Chief Scientific Officer at the beginning of 2023, leading the scientific teams in all phases of drug discovery and platform development, as well as building and overseeing the strategic technical direction of the company.
Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates designed to guide T cells to overcome chronic infectious diseases and autoimmunity. As part of its pipeline, Barinthus Bio is developing VTP-300, an immunotherapeutic product candidate that is designed as a potential component of a functional cure for chronic hepatitis B (CHB).
Prior to Barinthus Bio, Dr. Pelletier served as project leader at the Novartis Institutes for Biomedical Research and prior to that Roche Pharma Research & Early Development, leading drug discovery efforts to restore the correct immune dynamics and immune control over chronic infectious diseases (mainly focused on CHB) and autoimmune conditions. Prior to these, Dr. Pelletier held scientist positions at Merck-Serono (Geneva, Switzerland), International AIDS Vaccine Initiative (IAVI, San Diego, CA), and The Scripps Research Institute (San Diego, CA).
